Therefore, a systematic stratification of tumours that goes beyond therapeutically actionable alterations and incorporates other functional readouts—for example, dysregulated TF and (phospho)protein signatures derived from our model—may better predict which patients will benefit from targeted and combination therapies. This evidence concerns the gene TF and neoplasm.